

## **Briefing Material**

for 2<sup>nd</sup> quarter ended Jun. 30, 2024

Aug. 9, 2024

NAKANISHI INC.

#### Disclaimer


The information presented in these materials contains forward-looking statements about future business performance. These statements by definition involve risks and uncertainties and are not intended to guarantee future performance. Actual results in the future may differ from expectations and the projections presented in these materials due to changes in the global economy and fluctuations in foreign currency exchange rates and so on.



#### Change in reporting segments

Key change

Presenting results of DCI, acquired in Aug. 2023, as an independent segment.



© 2024 NAKANISHI INC.



## **Product lineup**

#### **Dental Business**



Handpiece



implant motor



Oral hygiene system



Clinical micro motor



#### **DCI Business**



Dental chair



Dental Parts (H.P. Cart)



Dental Parts (Syringe)

#### **Surgical Business**



Console



Slim motor



Attachment




Bur

#### **Industrial Business**



Controller&Spindle



Spindle



Network interface module



Ultrasonic Cutter



#### Performance highlights of FY2024 Q2

onsolidated net sales was increased by 36% (vs. 2023Q2) due to the depreciation of the yen and the effects of acquisitions. Sales increased in Dental, DCI and Surgical segments, while decreased significantly in Industrial segment.

BITDA was increased by double-digit, reaching over 11 billion yen, mainly boosted by FOREX and M&A.

he full-year financial forecasts has been revised upward considering actual results for the first half and the current exchange rates, although the business environment is assumed to remain challenging until the end of the fiscal year.

\* Retrospective adjustment was made for the results for 2023Q2 following the completion of the PPA of acquired company (JAEGER).



#### Consolidated P/L



	FY2024Q2	FY2023Q2	YoY con	nparison
	Actual	Actual	Amount	Ratio
Net sales	38,557	28,259	+10,297	+36.4%
Gross Profit	22,863	17,793	+5,070	+28.5%
Ratio to net sales	59.3%	63.0%	-3.7pt	_
EBITDA *	11,051	9,379	+1,672	+17.8%
Margin	28.7%	33.2%	-4.5pt	_
Operating Profit	8,287	8,038	+248	+3.1%
Ratio to net sales	21.5%	28.4%	-7.0pt	_
Ordinary Profit	10,522	11,039	-517	-4.7%
Ratio to net sales	27.3%	39.1%	-11.8pt	_
Profit attributable to owners of parent	7,026	7,972	-945	-11.9%
Ratio to net sales	18.2%	28.2%	-10.0pt	_
EPS (JPY)	82.88	93.74	<del>_</del>	_
* EBITDA = Operating profit + Depreciation + Amortiza	tion			
Currency rate - Against the US dollar (JPY)	152.31	135.99	+16.32	

(JPY)

- Against the EURO

164.83

147.01

+17.82

<sup>•</sup> Forex impact: Net sales +3,209M of JPY (vs FY2023Q2 Actual), +3,147M of JPY (vs FY2024 Forecast)



## Reference data: Consolidated P/L excluding DCI and Refine




	Reference data excluding DCI and REFINE	Reference data excluding DCI and REFINE	YoYcoı	mparison
	FY2024Q2 Actual	FY2023Q2 Actual	Amount	Ratio
Net sales	27,796	28,259	-462	-1.6%
Gross profit	18,543	17,793	+750	+4.2%
Ratio to net sales	66.7%	63.0%	+3.7pt	_
EBITDA *	9,444	9,379	+64	+0.7%
Margin	34.0%	33.2%	+0.8pt	_
Operating profit	8,001	8,038	-37	-0.5%
Ratio to net sales	28.8%	28.4%	+0.3pt	_
Ordinary profit	10,212	11,039	-826	-7.5%
Ratio to net sales	36.7%	39.1%	-2.3pt	_
Profit attributable to owners of parent	7,069	7,972	-902	-11.3%
Ratio to net sales	25.4%	28.2%	-2.8pt	_
EPS (JPY)	83.38	93.74	_	_
* EBITDA = Operating profit + Depreciation + An	nortization			
Currency rate - Against the US dollar (JPY)	152.31	135.99	+16.32	-
- Against the EURO (JPY)	164.83	147.01	+17.82	-

<sup>•</sup> Forex impact: Net sales +2,083M of JPY (vs FY2023Q2 Actual), +1,938M of JPY (vs FY2024 Forecast)



## Change in net sales by business segment





	FY2023Q2 Actual	FY2024Q2 Actual	Change			
Dental	22,448	23,335	+3.9%			
DCI	-	9,933				
Surgical	1,779	2,022	+13.7%			
Industrial	4,031	3,266	-19.0%			
Total	28,259	38,557	+36.4%			
Forex impact		+2,083M of J	PY (+7.4%)			
M&A effect (DCI and Refine) +10,760M of JPY (+38.1%)						

Reference:


DCI's net sales in FY2023Q2

7,751M of JPY (unaudited) (1USD=133.26JPY)



## Change in net sales by region






	FY2023Q2 Actual	FY2024Q2 Actual	Change		
Japan	5,120	4,648	-9.2%		
Europe	9,596	10,103	+5.3%		
N. America	4,578	15,284	+233.8%		
Asia	4,483	4,517	+0.8%		
Others	4,480	4,002	-10.7%		
Total	28,259	38,557	+36.4%		
Forex impact +2,083M of JPY (+7.4%)					
M&A effect (DCI and Refine) +10,760M of JPY (+38.1%)					



#### Change in EBITDA by business segment





	FY2023Q2 Actual	FY2024Q2 Actual	Change
Dental	9,825	10,237	+4.2%
DCI *	-5	1,585	-
Surgical	928	1,106	+19.2%
Industrial	931	703	-24.5%
Corporate expenses	-2,301	-2,581	-
Total	9,379	11,051	+17.8%
Foreximpact		+453M of .	JPY (+4.8%)
M&A effect (D	OCI and Refine)	+1,578M of .	JPY (+16.8%)


#### Reference:

- \*DCI's EBITDA in FY2023Q2
- 1,190M of JPY (unaudited) (1USD=133.26PY)
- \*DCI's EBITDA in FY2023Q2 includes the profit and loss of NAH, an intermediate holding company.



#### Change in EBITDA








## Other income / Expense, Taxes





Non-operating profit	<ul><li>Interest income</li><li>Foreign exchange gain</li><li>Miscellaneous income</li></ul>	281 1,563 204
Non-operating expenses	<ul><li>Interest expenses</li><li>Miscellaneous losses</li></ul>	23 17
Extraordinary losses	<ul><li>Loss on retirement of non-current assets</li><li>Expense on scrapping fixed assets</li></ul>	19 23



## Consolidated balance sheet




	As of Jun. 30, 2024	As of Dec. 31, 2023	Change	Notes	
Total assets	156,758	140,768	+15,989	Buildings and structures     Construction in progress	+4,836 -3,136
- Cash and deposits	39,324	31,718	+7,606		,
- Inventories	26,265	24,016	+2,249	<ul> <li>Merchandise and finished goods</li> <li>Work in process</li> <li>Raw materials and supplies</li> </ul>	+1,050 +645 +553
- Goodwill	23,352	21,378	+1,973		
Liabilities	32,722	27,603	+5,118	· Accounts payable - trade · Current liabilities - other	+536 +503
- Loans payable	14,489	11,668	+2,821	<ul> <li>Current portion of long-term borrowings</li> <li>Long-term borrowings</li> </ul>	s +1,001 +1,768
Net assets	124,035	113,164	+10,870	<ul><li>Treasury shares</li><li>Foreign currency translation adjustment</li></ul>	-866 +7,574
- Retained earnings	117,119	112,310	+4,808		
Return on equity	11.9%	22.4%	-10.5pt		
Return on assets	14.1%	14.2%	-0.1pt		

	FY2024Q2 Actual	FY2023Q2 Actual	Change	Notes	
Capital investments	2,458	3,113	-654	<ul><li>M1 factory</li><li>Machinery and equipment</li></ul>	1,085 536
Depreciation expenses	1,975	1,239	+735		



#### Consolidated statements of cash flows



© 2024 NAKANISHI INC.



# Revisionof consolidated financial forecast for FY2024

© 2024 NAKANISHI INC.



## Revision of consolidated financial forecast for FY2024

M of JPY	Revised forecast for FY2024	Previous forecast for FY2024		ious Fcst	FY2023 Actual	YoY cor	nparison
	announced on Aug. 9	announced on Feb. 13	Amount	Ratio		Amount	Ratio
Net sales	75,208	74,432	+776	+1.0%	59,692	+15,516	+26.0%
Gross Profit	43,669	41,324	+2,345	+5.7%	36,092	+7,577	+21.0%
Ratio to net sales	58.1%	55.5%	+2.5pt	_	60.5%	-2.4pt	_
EBITDA*	19,013	17,770	+1,242	+7.0%	17,710	+1,302	+7.4%
Margin	25.3%	23.9%	+1.4pt	_	29.7%	-4.4pt	_
Operating Profit	13,427	12,652	+775	+6.1%	14,251	-824	-5.8%
Ratio to net sales	17.9%	17.0%	+0.9pt	_	23.9%	-6.0pt	_
Ordinary Profit	14,635	13,088	+1,547	+11.8%	17,193	-2,557	-14.9%
Ratio to net sales	19.5%	17.6%	+1.9pt	_	28.8%	-9.3pt	_
Profit attributable to owners of parent	9,652	8,894	+758	+8.5%	22,799	-13,147	-57.7%
Ratio to net sales	12.8%	11.9%	+0.9pt	_	38.2%	-25.4pt	_
EPS (JPY)	113.85	104.28	_	_	267.62	_	_
* EBITDA = Operating profit + Deprecia	ation + Amortization						
Assumed Currency rate (Annual average	e) Revised forecast	Previous forecast	change				
- Against the US dollar (JPY)	146.00	135.00	+11.00	Assum	ned exchange rate for 2nd-	half 1USD = 140.00 1EUR = 155.00	
- Against the EURO (JPY)	159.00	150.00	+9.00	Forex		of JPY(Annual net s of JPY(Annual net s	




## Reference date: Revision of consolidated financial forecast for FY2024 excluding DCI and Refine

MofJPY	Revised forecast excluding DCI and REFINE	Previous forecast excluding DCI and REFINE	vs. Prev	ious Fcst	FY2023 Actual excluding DCI and REFINE	YoY cor	nparison
	announced on Aug. 9	announced on Feb. 13	Amount	Ratio		Amount	Ratio
Net sales	55,225	55,648	-422	-0.8%	55,335	-110	-0.2%
Gross Profit	35,944	34,405	+1,539	+4.5%	34,979	+964	+2.8%
Ratio to net sales	65.1%	61.8%	+3.3pt		63.2%	+1.9pt	
EBITDA*	17,105	16,428	+676	+4.1%	17,754	-649	-3.7%
Margin	31.0%	29.5%	+1.5pt	_	32.1%	-1.1pt	_
Operating Profit	14,180	13,523	+657	+4.9%	14,948	-768	-5.1%
Ratio to net sales	25.7%	24.3%	+1.4pt	_	27.0%	-1.3pt	_
Ordinary Profit	15,370	13,971	+1,398	+10.0%	18,082	-2,712	-15.0%
Ratio to net sales	27.8%	25.1%	+2.7pt		32.7%	-4.8pt	_
Profit attributable to owners of parent	10,633	9,893	+739	+7.5%	12,180	-1,547	-12.7%
Ratio to net sales	19.3%	17.8%	+1.5pt	_	22.0%	-2.8pt	_
EPS (JPY)	125.42	115.99	_	_	142.97	_	_
* EBITDA = Operating profit + Deprecia	ation + Amortization						
Assumed Currency rate (Annual average	Revised forecast	Previous forecast	change				
- Against the US dollar (JPY)	146.00	135.00	+11.00	Assum	ned exchange rate for 2nd-h	alf 1USD = 140.00 1EUR = 155.00	
- Against the EURO (JPY)	159.00	150.00	+9.00	Forex	sensitivity USD 216 M EUR 93 M	of JPY(Annual net s of JPY(Annual net s	sales) sales)



## Change in net sales by business segment





	FY2023 Actual	Previous forecast Feb. 13	Revised forecast Aug. 9	Change
Dental	44,366	46,809	46,654	+5.2%
DCI	3,974	16,412	17,846	-
Surgical	(OctDec.) 3,770	(JanDec.) 3,994	(JanDec.) 4,352	+15.4%
Industrial	7,581	7,215	6,355	-16.2%
Total	59,692	74,432	75,208	+26.0%

Forex impact (YoY comparison) +2,137 M of JPY (+3.6%)

M&A effect (YoY comparison) +14,937 M of JPY (+25.0%)

<sup>\*</sup>DCI's results were included and presented under Dental business segment in FY2023, but in this slide, it is separated and presented individually based on business segment as of FY2024.



## Change in EBITDA



